Autoimmune hepatitis epidemiology and demographics
|
Autoimmune hepatitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Autoimmune hepatitis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Autoimmune hepatitis epidemiology and demographics |
|
Autoimmune hepatitis epidemiology and demographics in the news |
|
Risk calculators and risk factors for Autoimmune hepatitis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: :Manpreet Kaur, MD [2]
Overview
Epidemiology and Demographics
Incidence
- The incidence of Autoimmune hepatitis is approximately 1 to 2 per 100,000 individuals worldwide.[1][2][3][4][5]
Prevalence
- The prevalence of Autoimmune hepatitis is approximately 11 to 25 per 100,000 individuals worldwide.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- Women are more commonly affected by Autoimmune hepatitis than men.
- The women to men ratio is approximately 3.6:1.[6][7]
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Werner M, Prytz H, Ohlsson B, Almer S, Björnsson E, Bergquist A, Wallerstedt S, Sandberg-Gertzén H, Hultcrantz R, Sangfelt P, Weiland O, Danielsson A (2008). "Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study". Scand. J. Gastroenterol. 43 (10): 1232–40. doi:10.1080/00365520802130183. PMID 18609163.
- ↑ Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H (1998). "Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population". Scand. J. Gastroenterol. 33 (1): 99–103. PMID 9489916.
- ↑ Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Gearry RB, Stedman CA (2010). "Population-based epidemiology study of autoimmune hepatitis: a disease of older women?". J. Gastroenterol. Hepatol. 25 (10): 1681–6. doi:10.1111/j.1440-1746.2010.06384.x. PMID 20880179.
- ↑ Primo J, Maroto N, Martínez M, Antón MD, Zaragoza A, Giner R, Devesa F, Merino C, del Olmo JA (2009). "Incidence of adult form of autoimmune hepatitis in Valencia (Spain)". Acta Gastroenterol. Belg. 72 (4): 402–6. PMID 20163033.
- ↑ Grønbæk L, Vilstrup H, Jepsen P (2014). "Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study". J. Hepatol. 60 (3): 612–7. doi:10.1016/j.jhep.2013.10.020. PMID 24326217.
- ↑ Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB (1998). "Immune phenotype of chronic liver disease". Dig. Dis. Sci. 43 (9): 2149–55. PMID 9753285.
- ↑ Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA (2008). "Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis". J. Hepatol. 48 (1): 140–7. doi:10.1016/j.jhep.2007.08.013. PMID 18023911.